On this page

TRIAMCINOLONE ACETONIDE

Prescription Veterinary ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
TRIAMCINOLONE ACETONIDE
Generic name
Triamcinolone Acetonide
Dosage form
Lotion
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
7
Packages
7
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Triamcinolone Acetonide .25 mg/mL 1014314 View
Triamcinolone Acetonide 1 mg/mL 1014314 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Lotion
Route of administration
Topical
Presentations
14

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
213559
Application type
ANDA · Abbreviated New Drug Application
Approval date
July 1, 2020
Sponsor
QUAGEN
Products on application
2
Submissions recorded
1
Products approved under application 213559.
Product Trade name Form Strength Ingredient Status TE Flags
213559-001 TRIAMCINOLONE ACETONIDE LOTION TRIAMCINOLONE ACETONIDE Prescription AT
213559-002 TRIAMCINOLONE ACETONIDE LOTION TRIAMCINOLONE ACETONIDE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 213559.
Type No. Action Status Date Review
Original application 1 Approved July 1, 2020 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250722). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250722 HUMAN PRESCRIPTION DRUG · 20241227 HUMAN PRESCRIPTION DRUG · 20221130

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Triamcinolone acetonide lotion, 0.1% is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply the 0.1% triamcinolone acetonide lotion to the affected area two to three times daily. Rub in gently. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a small amount of lotion into the lesion until it disappears. Reapply the preparation leaving a thin coating on the lesion, cover with pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply triamcinolone acetonide lotion under an occlusive dressing in the evening and to remove the dressing in the morning (i.e.,12-hour occlusion). When utilizing the 12‐hour occlusion regimen, additional lotion should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Description

openFDA Drug Labeling

DESCRIPTION Triamcinolone Acetonide Lotion, USP is supplied in the following strengths: 0.025%, 0.1%. Each mL of Triamcinolone Acetonide Lotion, USP, 0.025%, 0.1% contains 0.25 mg, 1 mg triamcinolone acetonide, USP in a lotion base containing citric acid, cetyl alcohol, dimethicone, polysorbate 20, propylene glycol, purified water, sorbitan monopalmitate, and stearyl alcohol. It may contain 10% citric acid solution or 10% sodium citrate solution for pH adjustment. Triamcinolone Acetonide is a topical corticosteroid known chemically as 9-Fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. The molecular formula is C 24 H 31 FO 6 . It has the following structure: image description

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS , General ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Triamcinolone acetonide lotion, USP 0.1%: plastic squeeze bottles containing 60 mL of lotion (NDC 42571-385-19) Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing. Shake well before using. Distributed by: Micro Labs USA, Inc. Somerset, NJ 08873 Manufactured by: Saptalis Pharmaceuticals, LLC Hauppauge, NY 11788 MADE IN USA 01/22-R2

Adverse event reports

Source: openFDA FAERS
31,697
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
72162-2069-6 72162-2069 Bryant Ranch Prepack 60 mL in 1 BOTTLE, WITH APPLICATOR (72162-2069-6) August 15, 2023
72162-2070-6 72162-2070 Bryant Ranch Prepack 60 mL in 1 BOTTLE, WITH APPLICATOR (72162-2070-6) August 15, 2023
0713-0676-53 0713-0676 Cosette Pharmaceuticals, Inc. 1 BOTTLE in 1 CARTON (0713-0676-53) / 60 mL in 1 BOTTLE September 13, 2016
42571-385-19 42571-385 MICRO LABS LIMITED 60 mL in 1 BOTTLE (42571-385-19) August 16, 2021
70752-129-05 70752-129 QUAGEN PHARMACEUTICALS LLC 60 mL in 1 BOTTLE, WITH APPLICATOR (70752-129-05) July 1, 2020
70752-130-05 70752-130 QUAGEN PHARMACEUTICALS LLC 60 mL in 1 BOTTLE, WITH APPLICATOR (70752-130-05) July 1, 2020
71656-040-60 71656-040 Saptalis Pharmaceuticals, LLC. 60 mL in 1 BOTTLE (71656-040-60) July 30, 2024
72162-2069 72162-2069 Bryant Ranch Prepack — July 1, 2020
72162-2070 72162-2070 Bryant Ranch Prepack — July 1, 2020
0713-0676 0713-0676 Cosette Pharmaceuticals, Inc. — September 13, 2016
42571-385 42571-385 MICRO LABS LIMITED — August 16, 2021
70752-129 70752-129 QUAGEN PHARMACEUTICALS LLC — July 1, 2020
70752-130 70752-130 QUAGEN PHARMACEUTICALS LLC — July 1, 2020
71656-040 71656-040 Saptalis Pharmaceuticals, LLC. — July 30, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.